



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) Nikolaos Berntenis, et. al.

Group:

Application No. 10/567,386, filed February 7, 2006  
(Case Docket No. 21796)

Examiner:

For: RA ANTIGENIC PEPTIDES

**INFORMATION DISCLOSURE STATEMENT**

Nutley, New Jersey 07110  
June 14, 2006

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.


Documents C1-C44 listed on Form PTO-1449 are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Appl. No. 10/567,386  
Filed: February 7, 2006

Since the Information Disclosure Statement is submitted before the receipt of the first Office Action on the merits for the above application, it is believed that no fee is due. If a fee is due and owing, please charge to Deposit Account No. 08-2525.


Respectfully submitted,



Attorney for Applicant(s)  
Dennis P. Tramaloni  
(Reg. No. 28,542)  
340 Kingsland Street  
Nutley, New Jersey 07110  
Telephone: (973) 235-4475  
Telefax: (973) 235-2363

242146

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		Application Number	10/567,386
		Filing Date	February 7, 2006
		First Name Inventor	Berntenis
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	21796
Sheet 1	Of 2		



### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C1	Mageed, R.A., et. al., Manual of Biological Markers of Disease, Kluwer Academic Pub (1996) 1-18	
	C2	Nakamura, R.M., J Clin Lab Anal 14 (2000) 305-313	
	C3	Visser, H., et. al., Arthritis Rheum 46 (2002) 357-365	
	C4	Schellekens, G.A., et. al., J. Clin Invest 101 (1998) 273-281	
	C5	Vincent, C., et. al., J Rheumatol 25 (1998) 838-846	
	C6	Symmons, DPM, et. al., J. Rheumatol 25 (1998) 1072-1077	
	C7	Anderson, JJ, et. al., Arthritis Rheum 43 (2000) 22-29	
	C8	Fries, J.F., et. al., Arthritis Rheum 36 (1993) 297-306	
	C9	Marrack, P., et. al., Nat Med 7 (2001) 899-905	
	C10	Stastny, P., Tissue Antigen 4 (1974) 571-579	
	C11	Wordsworth, P., et. al., PNAS 86 (1989) 10049-10053	
	C12	Wordsworth, P., et. al., Springer Semin Immunopathol 14 (1992) 59-78	
	C13	Reveille, J., Curr Opin Rheumatol 10 (1998) 187-200	
	C14	Banchereau, J., et. al., Nature 392 (1998) 245-252	
	C15	Striebich, C.C., et. al., J Immunol 161 (1998) 4428-4436	
	C16	Stern, L.J., et. al., Nature 368 (1994) 215-221	
	C17	Messaoudi, et. al., Science 298 (2002) 1797-1800	
	C18	Jones, E.Y., Curr Opin Immunol 9 (1997) 75-79	
	C19	Gregersen, P.K., et. al., Arthritis Rheum 30 (1987) 1205-1213	
	C20	Corrigall, V.M., Crit Rev Immunol 22 (2002) 281-293	
	C21	Banerjee, S., et. al., Clin Exp Rheumatol 6 373-380	
	C22	Snowden, N., et. al., Rheumatology 40 (1997) 1210-1218	
	C23	Rosloniec, E.F., et. al., J Exp Med 185 (1997) 1113-1122	
	C24	Rosloniec, E.F., et. al., J Immunol 160 (1998) 2573-2578	
	C25	Fugger, et. al., Eur J Immunol 26 (1996) 928-933	
	C26	Kim, HY, et. al., Arthritis Rheum 42 (1999) 2085-2093	
	C27	Vos, K. et. al., Ann Rheum Dis 59 (2000) 544-548	
	C28	Verheijden, G.F., et. al. Arthritis Rheum 40 (1997) 1115-1125	
	C29	Cope, A.P., et. al. Arthritis Rheum 42 (1999) 1497-1507	
	C30	Baeten, D., et. al., Arthritis Rheum 43 (2000) 1233-1243	
	C31	Kotzin, B.L., et. al. PNAS 97 (2000) 291-296	
	C32	Kropshofer, et. al., J Exp Med 175 (1992) 1799-1803	
	C33	Chicz, R.M., et. al., J Exp Med 178 (1993) 27-47	
	C34	Dongre, A.R., et. al. Eur J Immunol 31 (2001) 1485-1494	
	C35	Engelhard, V.H., et. al., mol Immunol 39 (2002) 127-137	

[illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

231968



*1/11/06*

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	<b>10/567,386</b>
	Filing Date	<b>February 7, 2006</b>
	First Named Inventor	<b>Berntenis</b>
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	<b>21796</b>

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<b>USPTO Form 1449; References</b>	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>		
Firm or Individual name	<b>Dennis P. Tramaloni</b>	
Signature		
Date	<b>06/14/2006</b>	

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	<b>Dennis P. Tramaloni</b>		
Signature		Date	<b>06/14/2006</b>

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.